Sales · healthcare · APACJul 202610 min read376 words

Modern cold calling for Series B companies: scaling without breaking for healthcare and life sciences in the APAC region

How Series B companies scale modern cold calling across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the APAC region.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install modern cold calling has to be shaped to that reality from day one.

Series B is the stress test for modern cold calling. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, connects per hour on ICP dials, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Modern cold calling is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of modern cold calling is power dialers that torch the list in a week, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on connects per hour on ICP dials outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run modern cold calling function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing modern cold calling deliberately for this market rather than importing a playbook designed for somewhere else.

cold callingoutbound callingphone prospectingcold calling for series Bscaling GTMcold calling for healthcare and life sciencescold calling in the APAC regionhealthcare and life sciences growth in the APAC region

Frequently asked questions

Sales · healthcare · APAC — answered

Does modern cold calling work for healthcare and life sciences in the APAC region?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market. The healthcare teams that install this get past procurement instead of dying in it.
How does modern cold calling change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible connects per hour on ICP dials.
What compensation model works for modern cold calling operators at Series B?
Outcome-linked on connects per hour on ICP dials, not activity-based.
What is the Series B stress point?
Power dialers that torch the list in a week, amplified by headcount. Fix the root, not the symptom.
What is the APAC-specific pitfall when running modern cold calling for healthcare?
Importing a playbook that was built for another market. In the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market — the install has to reflect that.

Growth Broker editorial

Filed under sales · healthcare · apac

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call